Press Releases AnaptysBio, Inc.

Equities

ANAB

US0327241065

Market Closed - Nasdaq Other stock markets 21:00:00 29/04/2024 BST			5-day change	1st Jan Change
21.3 ^USD	+1.43%		+8.34%	-0.56%

04-16	Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target	MT
04-11	Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	03-11	GL
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting	02-29	GL
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting	02-29	AQ
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference	01-31	GL
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference	01-31	AQ
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals	11-27	GL
Anaptys Named a BioSpace 2024 Best Places to Work Winner	11-07	GL
Anaptys Named a BioSpace 2024 Best Places to Work Winner	11-07	AQ
Acne Vulgaris Pipeline\| Clinical Trials, Key Companies - Novan, Bausch Health AOBiome, Ascletis Pharmaceuticals, AnaptysBio, Botanix Pharmaceuticals	11-07	AQ
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update	11-02	GL
Anaptys Announces Participation in November Investor Conferences	11-01	GL
Anaptys Announces Participation in November Investor Conferences	11-01	AQ
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress	11/10/23	GL
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress	11/10/23	AQ
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25	09/10/23	GL
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25	09/10/23	AQ
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)	09/10/23	GL
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors	18/09/23	GL
AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit	12/09/23	GL
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update	07/08/23	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases AnaptysBio, Inc.

Equities

ANAB

US0327241065

Press Releases

Filters